A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer.

Trial Profile

A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Sep 2012 Planned End Date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top